Objective: The aim of this research was to investigate the effects of subacute use of lithium carbonate (Li2CO3), on serum T3, T4, thyroid stimulating hormone (TSH), parathyroid hor-mone (PTH) and calcium (Ca) levels and thyroid tissue. In addition, this research is important as one of the rare studies in which thyroid tissue was subjected to histological examination.Methods: Thirty-two male Sprague Dawley rats were assigned into groups consisting of eight animals each, based on weight; Group 1: Sham control, Group 2: Li2CO3+25 mg/kg, Group 3: Li2CO3+50 mg/kg and Group 4: Li2CO3+100 mg/kg. Li2CO3 was administered orally at varying concentrations, at 1 mL per day for 30 days. Serum samples were separated from blood obtained by intracardiac intervention. Serum T3, T4, TSH, PTH and Ca levels were measured by using an autoanalyzer and chemiluminescence. Thyroid tissue was examined under light microscopy after routine histopathological procedures.Results: T3, T4, PTH and Ca levels increased in rats treated with high-dose Li2CO3, where-as TSH levels were very low in all groups. In addition, thyroid tissue exhibited concentra-tion-dependent histological alterations.Conclusion: Li2CO3, which was administered subacute high dose in rats, caused of in-creased T4 and T3 hormones levels, hyperparathyroidism and hypercalcemia in the early period. These results now need to be supported by further experimental and clinical studies.
Amaç: Bu araştırmanın amacı, subakut lityum karbonat (Li2CO3) kullanımının serum T3, T4, tiroid uyarıcı hormon (TSH), paratiroid hormon (PTH) ve kalsiyum düzeyleri ve tiroid dokusu üzerindeki etkilerini araştırmaktır. Ayrıca, bu araştırma tiroid dokusunun histolojik incelemeye tabi tutulduğu nadir çalışmalardan biri olarak önemlidir.Gereç ve Yöntem: Otuz iki erkek Sprague Dawley sıçanı ağırlık bazında her biri sekiz hayvandan oluşan dört gruba ayrıldı; Grup 1: Sham kontrolü, Grup 2: Li2CO3+25 mg/kg, Grup 3: Li2CO3+50 mg/kg ve Grup 4: Li2CO3+100 mg/kg. Li2C03, 30 gün boyunca günde 1 ml olarak değişen konsantrasyonlarda oral yoldan uygulandı. Serum örnekleri intrakardiyak müdahale ile elde edilen kandan ayrıldı. Serum T3, T4, TSH, PTH ve Ca seviyeleri bir otoanalizör ve kemilüminesans kullanılarak ölçüldü. Tiroid dokusu rutin histopatolojik işlemlerden sonra ışık mikroskobu altında incelendi.Bulgular: Yüksek doz Li2CO3 ile tedavi edilen sıçanlarda T3, T4, PTH ve Ca seviyeleri yükselirken, TSH düzeyleri tüm gruplarda çok düşük-tü. Ek olarak, tiroid dokusu konsantrasyona bağlı histolojik değişiklikler sergiledi.Sonuç: Sıçanlarda subakut yüksek doz uygulanan Li2CO3 erken dönemde T4 ve T3 hormon düzeylerinde artış, hiperparatiroidizm ve hiper-kalsemiye neden olmuştur. Bu sonuçların artık daha ileri deneysel ve klinik çalışmalarla desteklenmesi gerekmektedir.
1. Shorter E. The history of lithium therapy. Bipolar Disord 2009;11(Suppl 2):4–9.
2. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential mechanisms of action of lithium in bipolar disorder. Current understanding. CNS Drugs 2013;27:135–53.
3. Buspavanich P, Behr J, Stamm T, Schlattmann P, Bschor T, Richter C, et al. Treatment response of lithium augmentation in geriatric compared to non-geriatric patients with treatment-resistant depression. J Affect Disord 2019;251:136–40.
4. Bowden CL. Bipolar pathophysiology and development of improved treatments. Brain Res 2008;1235:92–7.
5. Fabbri C, Serretti A. Genetics of long-term treatment outcome in bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry 2016;65:17–24.
6. Hidalgo-Mazzei D, Berk M, Cipriani A, Cleare AJ, Florio AD, Dietch D, et al. Treatment-resistant and multi-therapy-resistant criteria for bipolar depression: consensus definition. Br J Psychiatry 2019;214:27–35.
7. Chandrasekaran V, Brennan-Olsen SL, Stuart AL, Pasco JA, Berk M, Hodge JM, et al. Association between bipolar spectrum disorder and bone health: a meta-analysis and systematic review protocol. BMJ Open 2017;7:e013981.
8. Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018;20:97–170.
9. Tohen M, Zarate CA Jr, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry 2003;160:2099–107.
10. Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord 2016;4:27.
11. Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemiol Ment Health 2006;2:23.
12. Webb AL, Solomon DA, Ryan CE. Lithium levels and toxicity among hospitalized patients. Psychiatr Serv 2001;52:229–31.
13. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin- releasing hormone. Thyroid 1998;8:909–13.
14. Barclay ML, Brownlie BE, Turner JG, Wells JE. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence. Clin Endocrinol (Oxf ) 1994;40:759–64.
15. Nair CG, Menon R, Jacob P, Babu M. Lithium-induced parathyroid dysfunction: A new case. Indian J Endocrinol Metab 2013;17:930–2.
16. Szalat A, Mazeh H, Freund HR. Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur J Endocrinol 2009;160:317–23.
17. Bendz H, Sjödin I, Toss G, Berglund K. Hyperparathyroidism and long-term lithium therapy--a cross-sectional study and the effect of lithium withdrawal. J Intern Med 1996;240:357–65.
18. Bhuvaneswar CG, Baldessarini RJ, Harsh VL, Alpert JE. Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009;23:1003–21.
19. Kuman Tunçel Ö, Akdeniz F, Özbek SS, Kavukçu G, Ünal Kocabaş G. The Effects of Lithium on Calcium and Parathormone Levels: A Cross-sectional Study with Healthy Controls. Turk Psikiyatri Derg 2019;30:163–71.
20. Delva NJ, Hawken ER. Preventing lithium intoxication. Guide for physicians. Can Fam Physician 2001;47:1595–600.
21. Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009;5:270–6.
22. Livingstone C, Rampes H. Lithium: a review of its metabolic adverse effects. J Psychopharmacol 2006;20:347–55.
23. Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab 2009;23:723–33.
24. Spaulding SW, Burrow GN, Bermudez F, Himmelhoch JM. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 1972;35:905– 11.
25. Siyam FF, Deshmukh S, Garcia-Touza M. Lithium-associated hyperthyroidism. Hosp Pract (1995) 2013;41:101–4.
26. Kibirige D, Luzinda K, Ssekitoleko R. Spectrum of lithium induced thyroid abnormalities: a current perspective. Thyroid Res 2013;6:3.
27. Fairbrother F, Petzl N, Scott JG, Kisely S. Lithium can cause hyperthyroidism as well as hypothyroidism: A systematic review of an under- recognised association. Aust N Z J Psychiatry 2019;53:384–402.
28. Talwar N, Mohan S, Ravi B, Andley M, Kumar A. Lithium-induced enlargement of a lingual thyroid. Singapore Med J 2008;49:254–5.
29. Mizukami Y, Michigishi T, Nonomura A, Nakamura S, Noguchi M, Takazakura E. Histological features of the thyroid gland in a patient with lithium induced thyrotoxicosis. J Clin Pathol 1995;48:582–4.
30. Lazarus JH, McGregor AM, Ludgate M, Darke C, Creagh FM, Kingswood CJ. Effect of lithium carbonate therapy on thyroid immune status in manic depressive patients: a prospective study. J Affect Disord 1986;11:155–60.
31. Carmaciu CD, Anderson CS, Lawton CA. Thyrotoxicosis after complete or partial lithium withdrawal in two patients with bipolar affective disorder. Bipolar Disord 2003;5:381–4.
32. Thompson CJ, Baylis PH. Asymptomatic Graves' disease during lithium therapy. Postgrad Med J 1986;62:295–6.
33. Kuman Tunçel Ö, Akdeniz F, Özbek SS, Kavukçu G, Ünal Kocabaş G. Thyroid Function and Ultrasonography Abnormalities in Lithium- Treated Bipolar Patients: A Cross-sectional Study with Healthy Controls. Noro Psikiyatr Ars 2017;54:108–15.
34. Shine B, McKnight RF, Leaver L, Geddes JR. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data. Lancet 2015;386:461–8.
35. Bandyopadhyay D, Nielsen C. Lithium-induced hyperthyroidism, thyrotoxicosis and mania: a case report. QJM 2012;105:83–5.
36. de Sousa Gurgel W, Dutra PE, Higa RA, da Costa CB, de Matos e Souza FG. Hyperthyroid rage: when bipolar disorder hides the real disorder. Clin Neuropharmacol 2015;38:38–9.
37. Skandarajah AR, Palazzo FF, Henry JF. Lithium-associated hyperparathyroidism: surgical strategies in the era of minimally invasive parathyroidectomy. World J Surg 2011;35:2432–9. 38. Ibrahim Y, Mohamed SE, Deniwar A, Al-Qurayshi ZH, Kandil E. Lithium-Associated Hyperparathyroidism: A Pooled Analysis. ORL J Otorhinolaryngol Relat Spec 2015;77:273–80.
39. Hanna RM, Hasnain H, Sangalang MD, Han J, Arasu A, Arman F, et al. Three Patients with Lithium-Associated Hyperparathyroidism: Literature Review Regarding Medical and Surgical Management. Case Rep Nephrol Dial 2019;9:108–18.
40. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987;10:329–45.
41. Hestbech J, Hansen HE, Amdisen A, Olsen S. Chronic renal lesions following long-term treatment with lithium. Kidney Int 1977;12:205–13.
42. Markowitz GS, Radhakrishnan J, Kambham N, Valeri AM, Hines WH, D'Agati VD. Lithium nephrotoxicity: a progressive combined glomerular and tubulointerstitial nephropathy. J Am Soc Nephrol 2000;11:1439–48.
43. Walker RG, Escott M, Birchall I, Dowling JP, Kincaid-Smith P. Chronic progressive renal lesions induced by lithium. Kidney Int 1986;29:875–81.
44. Gupta N, Gibson M, Wallace EC. Lithium-Induced Chronic Kidney Disease in a Pediatric Patient. Case Rep Pediatr 2019;2019:5406482.